These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 28543950)

  • 1. Approach to Fingolimod-Induced Lymphopenia in Multiple Sclerosis Patients: Do We Have a Roadmap?
    Avasarala J; Jain S; Urrea-Mendoza E
    J Clin Pharmacol; 2017 Nov; 57(11):1415-1418. PubMed ID: 28543950
    [No Abstract]   [Full Text] [Related]  

  • 2. Aggressive cutaneous leishmaniasis in a patient with multiple sclerosis treated with fingolimod.
    Hernández Clares R; Sánchez Pedreño P; García Vazquez E; Carreón Guarnizo E; Meca Lallana JE
    Neurologia (Engl Ed); 2018 Jun; 33(5):348-349. PubMed ID: 28535923
    [No Abstract]   [Full Text] [Related]  

  • 3. Merkel cell carcinoma in a patient with relapsing-remitting multiple sclerosis treated with fingolimod.
    Calvi A; De Riz M; Lecchi E; Pietroboni A; Ghezzi L; Scarioni M; Carandini T; Pellegrinelli A; Maurichi A; Galimberti D; Scarpini E
    J Neurol Sci; 2017 Oct; 381():296-297. PubMed ID: 28991701
    [No Abstract]   [Full Text] [Related]  

  • 4. Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis.
    Ward MD; Jones DE; Goldman MD
    Mult Scler Relat Disord; 2016 Sep; 9():47-9. PubMed ID: 27645342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple sclerosis rebound after fingolimod discontinuation for lymphopenia.
    La Mantia L; Prone V; Marazzi MR; Erminio C; Protti A
    Neurol Sci; 2014 Sep; 35(9):1485-6. PubMed ID: 24756193
    [No Abstract]   [Full Text] [Related]  

  • 6. Warts and all: Fingolimod and unusual HPV-associated lesions.
    Triplett J; Kermode AG; Corbett A; Reddel SW
    Mult Scler; 2019 Oct; 25(11):1547-1550. PubMed ID: 30427266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypothyroidism in multiple sclerosis patient during fingolimod treatment.
    Flores J; Rito Y; Torres G; Jung H; Treviño-Frenk I; Corona T
    J Neurol Sci; 2015 Jan; 348(1-2):272-3. PubMed ID: 25491264
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis.
    Tagawa A; Ogawa T; Tetsuka S; Otsuka M; Hashimoto R; Kato H; Ando K; Tanabe H
    Mult Scler Relat Disord; 2016 Sep; 9():155-7. PubMed ID: 27645365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod.
    Fragoso YD; Spelman T; Boz C; Alroughani R; Lugaresi A; Vucic S; Butzkueven H; Terzi M; Havrdova E; Horakova D; Granella F; Olascoaga J; Sánchez-Menoyo JL; Pucci E; Barnett M; Brooks JBB; Haartsen J;
    Mult Scler Relat Disord; 2018 Jan; 19():105-108. PubMed ID: 29182993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fingolimod-associated macular oedema.
    Jasani KM; Sharaf N; Rog D; Aslam T
    BMJ Case Rep; 2017 Jun; 2017():. PubMed ID: 28619738
    [No Abstract]   [Full Text] [Related]  

  • 11. Severe lymphopenia switching from Fingolimod to Siponimod.
    Sparaco M; Miele G; Bonavita S
    Neurol Sci; 2021 Nov; 42(11):4837-4838. PubMed ID: 34390419
    [No Abstract]   [Full Text] [Related]  

  • 12. Varicella-zoster virus vasculopathy in a multiple sclerosis patient on fingolimod.
    Muccilli A; Nehme A; Labrie M; Girard M; Odier C; Poppe AY
    J Neurol Sci; 2019 Aug; 403():119-121. PubMed ID: 31276860
    [No Abstract]   [Full Text] [Related]  

  • 13. Fingolimod-associated PML in a patient with prior immunosuppression.
    Gyang TV; Hamel J; Goodman AD; Gross RA; Samkoff L
    Neurology; 2016 May; 86(19):1843-5. PubMed ID: 27164718
    [No Abstract]   [Full Text] [Related]  

  • 14. A pragmatic approach to dealing with fingolimod-related lymphopaenia in Europe.
    Giovannoni G; de Jong B; Derfuss T; Izquierdo G; Mazibrada G; Molyneux P; Nicholas R; Overell J; Ziemssen T; Juliusson G
    Mult Scler Relat Disord; 2015 Jan; 4(1):83-4. PubMed ID: 25787058
    [No Abstract]   [Full Text] [Related]  

  • 15. Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis.
    Sharim J; Tashjian R; Golzy N; Pouratian N
    J Clin Neurosci; 2016 Aug; 30():166-168. PubMed ID: 26970935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virus-related Merkel cell carcinoma complicating fingolimod treatment for multiple sclerosis.
    Beadnall HN; Gill AJ; Riminton S; Barnett MH
    Neurology; 2016 Dec; 87(24):2595-2597. PubMed ID: 27856777
    [No Abstract]   [Full Text] [Related]  

  • 17. Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis.
    Christopher KL; Elner VM; Demirci H
    Ophthalmic Plast Reconstr Surg; 2017; 33(3):e73-e75. PubMed ID: 27533512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ventricular tachycardia after initiation of fingolimod.
    Elounais F; Aburahma A; Alkotob ML; Al Hadidi S
    BMJ Case Rep; 2017 Sep; 2017():. PubMed ID: 28954755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cryptococcal meningoencephalitis in an IgG
    Wienemann T; Müller AK; MacKenzie C; Bielor C; Weyers V; Aktas O; Hartung HP; Kremer D
    BMC Neurol; 2020 Apr; 20(1):158. PubMed ID: 32340606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unusual adverse dermatologic conditions associated with fingolimod and natalizumab in a patient with relapsing remitting multiple sclerosis.
    Mukharesh L; Maloni H; Maiberger M; Chen W; Wallin M
    Clin Neurol Neurosurg; 2020 Aug; 195():105886. PubMed ID: 32470781
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.